

Citibank N.A.
Securities Services
FIFC, 09th Floor,
C-54 & C-55, G-Block,
Bandra Kurla Complex,
Bandra (East)
Mumbai – 400 098, India

T +91 22 6175 7999 / 4502 7999
F +91 22 2653 2348



Dated: 24th June 2024

To,
**The Legal & Compliance Division,
National Stock Exchange,
Exchange Plaza, B.K.C.
Bandra (E)
Mumbai - 4000051**

Reporting under Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India ("SEBI")

Dear Sir,

We on behalf of and as authorized representatives of our below mentioned client wish to make the necessary disclosures as required under the **Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India ("SEBI")**


Please find below the relevant details in this regard for your ready reference. In this connection, we have also enclosed herewith the necessary disclosure forms.

Name of the acquirer & PAC with the acquirer	ORBIMED ASIA III MAURITIUS LIMITED
SEBI Registration No.	IN-MU-FP-1690-17
Scrip	ADVANCED ENZYME TECHNOLOGIES LIMITED
Total Holdings (No. of Shares)	0.00
Paid Up Equity Capital (No. of Shares)	111,824,075
% Fluctuation	9.88 % (Last reporting done at 9.88 %)
Current % Holding	0.00 %

In view of the aforesaid, you are requested to take this on records and do the needful. For any further queries in this regard, please contact us on 91-22-6175 6960.

Thanking You,

Truly Yours,
By Constituted Attorney


Sagar Madan
Enclosures: As above.